Abstract
Spero Therapeutics will receive up to $54 million from U.S. government agencies to develop its carbapenem-class antibiotic SPR994. The Biomedical Advanced Research & Development Authority is providing $15.7 million now, and up to $28.5 million over the next five years, to help fund clinical trials of the antibiotic. The remainder of the funds will come from the Defense Threat Reduction Agency. SPR994 is an oral formulation of Meiji Seika Pharma’s tebipenem, which has long been approved in Japan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
